Insilico Medicine Clarifies Secondary Listing Plans; No Decision on Abu Dhabi Move

Bulletin Express

05/27

Insilico Medicine Cayman TopCo (“Insilico Medicine”) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as Abu Dhabi—no definitive decision has been reached to pursue such a listing.

The Board stated it will release further announcements in line with Hong Kong Stock Exchange requirements should any material developments arise. Until then, shareholders and investors are advised to approach trading in the company’s securities with caution.

The voluntary announcement, dated 27 May 2026 and signed by Chairman and CEO Dr. Aleksandrs Zavoronkovs, reiterates that all strategic capital market actions remain under evaluation. The current board comprises two executive directors, three non-executive directors and three independent non-executive directors.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1194503614"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1194503614\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1194503614?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-27 12:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194503614","market":"us","top_or_hot":-1,"title":"Insilico Medicine Clarifies Secondary Listing Plans; No Decision on Abu Dhabi Move","media":"Bulletin Express","content":"<p>Insilico Medicine Cayman TopCo (“Insilico Medicine”) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as Abu Dhabi—no definitive decision has been reached to pursue such a listing.</p>\n<p>The Board stated it will release further announcements in line with Hong Kong Stock Exchange requirements should any material developments arise. Until then, shareholders and investors are advised to approach trading in the company’s securities with caution.</p>\n<p>The voluntary announcement, dated 27 May 2026 and signed by Chairman and CEO Dr. Aleksandrs Zavoronkovs, reiterates that all strategic capital market actions remain under evaluation. The current board comprises two executive directors, three non-executive directors and three independent non-executive directors.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Insilico Medicine Clarifies Secondary Listing Plans; No Decision on Abu Dhabi Move</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInsilico Medicine Clarifies Secondary Listing Plans; No Decision on Abu Dhabi Move\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-05-27 12:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Insilico Medicine Cayman TopCo (“Insilico Medicine”) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as Abu Dhabi—no definitive decision has been reached to pursue such a listing.</p>\n<p>The Board stated it will release further announcements in line with Hong Kong Stock Exchange requirements should any material developments arise. Until then, shareholders and investors are advised to approach trading in the company’s securities with caution.</p>\n<p>The voluntary announcement, dated 27 May 2026 and signed by Chairman and CEO Dr. Aleksandrs Zavoronkovs, reiterates that all strategic capital market actions remain under evaluation. The current board comprises two executive directors, three non-executive directors and three independent non-executive directors.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03696","symbol_name":"英矽智能","start_time":0,"source_url":"","article_id":"1194503614","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194503614","pubTimestamp":1779856986,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Insilico Medicine Cayman TopCo (「Insilico Medicine」) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03696":"英矽智能"},"translate_title":"英矽智能明确二次上市计划；阿布扎比搬迁尚未做出决定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03696":1},"content_text":"Insilico Medicine Cayman TopCo (「Insilico Medicine」) confirmed that, while it routinely reviews post-listing capital options—including the possibility of a secondary listing in other markets such as Abu Dhabi—no definitive decision has been reached to pursue such a listing.\nThe Board stated it will release further announcements in line with Hong Kong Stock Exchange requirements should any material developments arise. Until then, shareholders and investors are advised to approach trading in the company’s securities with caution.\nThe voluntary announcement, dated 27 May 2026 and signed by Chairman and CEO Dr. Aleksandrs Zavoronkovs, reiterates that all strategic capital market actions remain under evaluation. The current board comprises two executive directors, three non-executive directors and three independent non-executive directors.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}